

## Identification and Management of Re-Feeding Syndrome

This guidance does not override the individual responsibility of health professionals to make appropriate decision according to the circumstances of the individual patient in consultation with the patient and / or carer. Health care professionals must be prepared to justify any deviation from this guidance.

### INTRODUCTION

This guideline has been developed to advise all healthcare professionals involved in providing nutritional support to malnourished patients.

This guideline explains re-feeding syndrome and outlines identification of individuals at risk. It discussed the main considerations when providing nutritional support in patients thought to be at risk of re-feeding syndrome.

For advice on patients starting the out of hours emergency enteral feed regimen please see the 'Out of Hours Emergency Enteral Feeding Guideline' WAHT-NUT-008

For advice on patients at risk of re-feeding syndrome who require parenteral nutrition regimens please also contact Pharmacy and refer to 'Parenteral Nutrition Guideline' WAHT-NUT-007.

Please be aware that re-feeding syndrome can also occur in patients receiving oral nutrition support, i.e. oral nutritional supplement drinks.

### THIS GUIDELINE IS FOR USE BY THE FOLLOWING STAFF GROUPS:

Qualified Doctors, qualified Nurses, Pharmacists and Dietitians.

#### Lead Clinician(s)

Dr Thea Haldane

Consultant Gastroenterologist

Approved by Nutrition and Hydration Committee:

16<sup>th</sup> October 2015

Approved by Medicines Safety Committee on:

14<sup>th</sup> October 2015

Review Date:

This is the most current document and is to be used until a revised version is available

6<sup>TH</sup> November 2020

**Key amendments to this guideline**

| Date                     | Amendment   | By:                               |
|--------------------------|---|-----------------------------------|
| January 2009             | Approved by Nutrition Steering Committee (nutrition and hydration committee) and Medicines Safety Committee |                                   |
| March 2011               | Who is at risk? Section amended and minor amendment to Re-feeding Syndrome flowchart                        | Jo Brown                          |
| June 2011                | Reformatting of protocol for prevention of re-feeding syndrome chart  | Jo Brown                          |
| March 2013               | Guideline expiry extended whilst under review   | Jo Brown                          |
| May 2013                 | Guideline expiry extended whilst under review   | Jo Brown                          |
| June 2013                | Guideline expiry extended whilst under review   | Jo Brown                          |
| August 2013              | Guideline expiry extended whilst under review   | Jo Brown                          |
| 29/10/2013               | Guideline has been extended for 6 months whilst under major review  | Nalinee Owen                      |
| 25/3/2014                | Guideline extended for 3 months   | Nalinee Owen                      |
| 24/11/2014               | Guideline extended for 3 months   | Nalinee Owen                      |
| 28/01/2015               | Guideline extended until 30 <sup>th</sup> April 2015  | Jo Brown                          |
| 24/04/2015               | Guideline extended until 30 <sup>th</sup> June 2015   | Jo Brown                          |
| 24/06/2015               | Guideline extended until 30 <sup>th</sup> September 2015  | David Aldulaimi                   |
| Sept. 2015               | Amendments to re-feeding syndrome protocol in line with NICE & BAPEN.                                       | Dr Haldane and the nutrition team |
| October 2017             | Document extended for further two years, no changes   | Dr Haldane                        |
| December 2017            | Sentence added in at the request of the Coroner   |                                   |
| 17/09/2019               | Document extended for 6 months to ensure current guidelines are adapted to new national guidelines          | Dr Haldane                        |
| 6 <sup>th</sup> May 2020 | Document extended for 6 months during COVID period  |                                   |

**Identification and Management of Re-Feeding Syndrome**

|  |       |
|--|-------|
| INTRODUCTION.....  | 3     |
| COMPETENCIES REQUIRED.....   | 3     |
| DETAILS OF GUIDELINE.....  | 3     |
| Pathogenesis of Re-feeding Syndrome.....                             | 3     |
| Consequences of Intracellular Shifts in Re-feeding Syndrome.....     | 4     |
| Who is at Risk?.....   | 5     |
| Recommendations to Manage and Prevent Re-feeding Syndrome.....       | 5     |
| Protocol for Prevention of Re-feeding Syndrome .....                 | 6     |
| Starting to Feed Safely.....   | 6     |
| MONITORING TOOL.....   | 7     |
| REFERENCES.....  | 8-9   |
| CONTRIBUTION LIST.....   | 10-11 |
| EQUALITY IMPACT ASSESSMENT TOOL.....                                 | 12    |
| FINANCIAL IMPACT ASSESSMENT.....                                     | 13    |
| APPENDIX 1 (ELECTROLYTE SUPPLEMENTATION IN RE-FEEDING SYNDROME)..... | 14    |

# Identification and Management of Re-Feeding Syndrome

## INTRODUCTION

This guideline has been developed to advise all healthcare professionals involved in providing nutritional support to malnourished patients.

This guideline explains re-feeding syndrome and outlines identification of individuals at risk. It discussed the main considerations when providing nutritional support in patients thought to be at risk of re-feeding syndrome.

Re-feeding syndrome is largely under diagnosed due to ethical issues of research and because clinicians are often unaware of its existence.

The majority of papers and literature that discuss re-feeding syndrome refer to the review paper by Solomon and Kirby in 1990, 2000 and more recently NICE (Feb, 2006) and BAPEN (Nov, 2012).

Prospective, non-interventional studies have been attempted to determine the incidence, risk factors and the clinical effects of re-feeding syndrome. The incidence of re-feeding syndrome is largely unknown as no universally accepted definition exists.


## COMPETENCIES REQUIRED:

All qualified staff involved in providing and delivering nutritional support to malnourished patients.  
All qualified Doctors, qualified Nurses, Pharmacists and Dietitians.

## DETAILS OF GUIDELINE

Re-feeding syndrome can occur when initiating all forms of nutrition support in malnourished or starved patients. For example patients who have had no or little nutrition for 5 or more days may become intracellularly depleted of potassium, magnesium and phosphate and deficient in B vitamins (especially thiamine).

## PATHOGENESIS OF RE-FEEDING SYNDROME



NB: Vitamin B is essential for carbohydrate metabolism


## CONSEQUENCES OF INTRACELLULAR SHIFTS IN RE-FEEDING SYNDROME

- Hypophosphataemia
- Hypokalaemia
- Hypomagnesaemia
- Altered glucose metabolism
- Fluid balance abnormalities
- Vitamin deficiencies

**CLINICAL SYMPTOMS OF RE-FEEDING SYNDROME (please refer to trust reference ranges for normal values)**

|                         | <b>Low Phosphate</b>   | <b>Low Potassium</b>  | <b>Low Magnesium</b>  | <b>Fluid/ Glucose</b>   |
|-------------------------|--|---|---|---|
| Cardiac                 | <ul style="list-style-type: none"> <li>Altered myocardial function</li> <li>Arrhythmia</li> <li>Congestive heart failure</li> </ul>  | <ul style="list-style-type: none"> <li>Arrhythmia</li> <li>Cardiac arrest</li> <li>ECG changes</li> </ul>   | <ul style="list-style-type: none"> <li>Arrhythmia</li> <li>Tachycardia</li> </ul>   | <ul style="list-style-type: none"> <li>Heart failure</li> </ul>   |
| Respiratory             | <ul style="list-style-type: none"> <li>Acute ventilatory failure</li> </ul>  | <ul style="list-style-type: none"> <li>Respiratory depression</li> </ul>  | <ul style="list-style-type: none"> <li>Respiratory depression</li> </ul>  | <ul style="list-style-type: none"> <li>Pulmonary oedema</li> <li>Respiratory depression</li> </ul>        |
| Hepatic                 | <ul style="list-style-type: none"> <li>Liver dysfunction</li> </ul>  | <ul style="list-style-type: none"> <li>Exacerbation of hepatic encephalopathy</li> </ul>  |   | <ul style="list-style-type: none"> <li>Fatty liver</li> </ul>   |
| Renal                   | <ul style="list-style-type: none"> <li>Acute renal failure</li> <li>Bicarbonate and glucose wasting</li> </ul>   | <ul style="list-style-type: none"> <li>Decreased urinary concentrating ability</li> <li>Polyuria &amp; Polydipsia</li> <li>Decreased GFR</li> </ul> | <ul style="list-style-type: none"> <li>Increased potassium loss</li> </ul>  |   |
| Gastro-intestinal tract | <ul style="list-style-type: none"> <li>Anorexia</li> <li>Nausea</li> </ul>   | <ul style="list-style-type: none"> <li>Constipation</li> <li>Ileus</li> </ul>   | <ul style="list-style-type: none"> <li>Abdominal pain</li> <li>Anorexia</li> <li>Diarrhoea</li> <li>Constipation</li> </ul> |   |
| Neuromuscular           | <ul style="list-style-type: none"> <li>Lethargy</li> <li>Weakness / paralysis</li> <li>Confusion</li> <li>Coma</li> <li>Diaphragm weakness</li> </ul>  | <ul style="list-style-type: none"> <li>Paralysis</li> <li>Rhabdomyolysis</li> <li>Weakness</li> </ul>   | <ul style="list-style-type: none"> <li>Ataxia</li> <li>Confusion</li> <li>Muscle tremors</li> <li>Tetany</li> </ul>         | <ul style="list-style-type: none"> <li>Hyperosmotic non-ketotic coma</li> </ul>                           |
| Haematological          | <ul style="list-style-type: none"> <li>Haemolytic anaemia</li> <li>WBC dysfunction</li> <li>Thrombocytopenia</li> <li>Haemorrhage</li> <li>Red cell 2,3 diphosphoglycerate deficiency</li> </ul> |   |   |   |
| Metabolic               | <ul style="list-style-type: none"> <li>Reduced oxygen release to tissues from haemoglobin</li> </ul>   | <ul style="list-style-type: none"> <li>Glucose intolerance</li> </ul>   | <ul style="list-style-type: none"> <li>Hypocalcaemia</li> <li>Hypokalaemia</li> </ul>                                       | <ul style="list-style-type: none"> <li>Hyperglycaemia</li> <li>Hypernatraemia or hyponatraemia</li> </ul> |

WHO IS AT RISK?



RECOMMENDATIONS TO MANAGE AND PREVENT RE-FEEDING SYNDROME

To increase awareness of what re-feeding syndrome is and who the ‘at risk’ patients are.

To check electrolytes before commencing nutrition support.

To replace electrolytes (unless otherwise indicated) whilst commencing and progressing nutritional support (whether this is via the oral, enteral or parenteral route).

To continue to monitor electrolytes and replace electrolytes (unless otherwise indicated) until the patient is receiving their target nutritional support.

Please note that ‘Forceval’ soluble tablet is not required for patients receiving parenteral nutrition as their vitamin and mineral requirements will be met within their parenteral nutrition prescription.

Please initiate and increase calorie delivery slowly in the “at risk” patient. The more rapidly calories are delivered, the greater demand on circulating electrolytes thus there will be an increased risk of re-feeding syndrome.

The re-feeding syndrome protocol can be seen overleaf which also appears on the reverse of the ‘out of hours’ feeding regimen (please refer to the ‘Out of Hours Enteral Feeding Guideline’) and on all enteral feed regimes provided by the Dietitians across the trust.

PROTOCOL FOR PREVENTION OF REFEEDING SYNDROME

**Re-feeding Syndrome: Identification of those at risk**

Establish BMI, degree of unintentional weight loss in the last 3-6 months, period of little or no nutritional intake, potassium, magnesium and phosphate levels and any history of excess alcohol or drugs such as insulin, chemotherapy, antacids and diuretics.

Has the patient had any one of the following:

- BMI < 16kg/m<sup>2</sup>
- Weight loss of >15% over the last 3-6 months
- Poor nutritional intake for 10 days
- Low electrolytes.

Has the patient had any two of the following:

- BMI < 18.5kg/m<sup>2</sup>
- Weight loss >10% over the last 3-6 months
- Poor nutritional intake for 5 days
- Drug history as above

Patient is at risk of re-feeding syndrome – follow the flow chart below and refer immediately to the Dietitian

- Prior to commencing nutrition prescribe thiamine and B vitamins to be given at least 30 minutes before and during the first 10 days of feeding: high dose thiamine (200-300mg/day) and Vit B Co strong 1-2 tablets which can also be given via NGT/PEG or consider IV Pabrinex - one pair of intravenous high potency ampoules in 100ml sodium chloride 0.9% over 15-30 minutes (this contains 250mg of Thiamine).
- Give 1 Forceval soluble tablet, dissolved in 125 - 200ml sterile water (Oral/NG/PEG) once daily until the Dietitian reviews (avoid giving during the feed break).

\*NB: if patient is not deemed at risk of re-feeding syndrome please follow the appropriate feeding regimen over page

**Starting to Feed Safely - In Patients at risk of Re-feeding Syndrome**

**Step 1:**

Commence enteral nutrition as per appropriate feeding regimen over page (if there are any concerns with swallow please refer to speech and language therapy).

**Step 2:**

Measure electrolytes: even if normal, replace potassium, phosphate and magnesium (see appendix 1 / discuss with pharmacy for guidance on electrolyte replacement). Only withhold supplementation if levels are high.

**Step 3:**

- Monitor potassium, magnesium, phosphate, calcium and sodium daily until bloods are normal and stable and the patient is receiving their target nutritional support, then continue to check bloods on a weekly basis.
- Continue to replace potassium, phosphate and magnesium (unless high) until the patient is receiving their target nutritional support.

**Step 4:**

- Monitor blood glucose levels (BMs) four times daily, as per BM chart.
- Monitor daily fluid balance.
- Doctors to assess the need for additional / replacement fluids on an individual basis. Unless contraindicated aim for 20-30ml/kg/day taking into account current fluid intake.

**NB. The more rapidly calories are delivered and the rate increased, the greater the demand on circulating electrolytes; thus there will be an increased risk of re-feeding.**

It is the responsibility of every individual to check that this is the latest version/copy of this document.

**MONITORING TOOL**

This should include realistic goals, timeframes and measurable outcomes.

How will monitoring be carried out?

Who will monitor compliance with the guideline?

| Page/<br>Section of<br>Key<br>Document | Key control:   | Checks to be carried out to confirm compliance with the policy:  | How often the check will be carried out: | Responsible for carrying out the check:   | Results of check reported to:<br><i>(Responsible for also ensuring actions are developed to address any areas of non-compliance)</i>  | Frequency of reporting: |
|--|--|--|--|---|---|-------------------------|
|  | <b>WHAT?</b>   | <b>HOW?</b>  | <b>WHEN?</b>                             | <b>WHO?</b>   | <b>WHERE?</b>   | <b>WHEN?</b>            |
|  | Were patients commenced on the appropriate out of hours feed regimen according to their re-feeding risk?<br><br>Was the feed regimen followed signed by a Doctor?<br><br>Was thiamine / vitamin B / Pabrinex / Forceval prescribed appropriately?<br><br>Were re-feeding bloods measured and supplemented if levels were normal?<br><br>Were re-feeding bloods monitored at appropriate intervals? | Foundation year 1 and 2 training session discussing nutrition, re-feeding and parenteral guidelines.<br><br>Retrospective audits | Annually<br><br>Twice per year           | Senior dietitian and senior pharmacist<br><br>Dr Haldane and the nutrition team | Results of the audit will be reported back to members of the nutrition and hydration committee. Audit results will also be reported back to appropriate directorates as necessary via Dr Haldane. | Twice a year            |

**REFERENCES**

B.D.A. Pen Group. December 1996. Dietetic standards for nutritional support.

BAPEN August 1996. Current perspectives in enteral nutrition in adults

Birmingham et al Division of Internal Medicine. University of British Columbia, Vancouver. A.N: Re-feeding and hypophosphataemia. International Journal of Eating Disorders 20 (2) 211 – 3 1996 September.

Birmingham Heartlands Hospital Enteral Feeding Guidelines year 2000

Bowling T. et al Department of Gastroenterology and Nutrition, Central Middlesex Hospital, London

British National Formulary 2001. Brit. Med. Assoc. & Royal Pharmaceutical Soc.

Brooks MJ. & Merrick G. The Re-feeding syndrome: an approach to understanding its complications and preventing its occurrence. Pharmacotherapy 1995 November – December 15 (6) 713 –26

Cheung J, Johnson, R. Refeeding syndrome. Student BMJ. Jan 2009

Crook M. Hypophosphataemia and Hypokalaemia in Patients with Hypomagnesaemia. Br. J. Biomed. Sci. 1994 : 51: 24 – 7

Crook M. Hypophosphataemia in an Hospital Population and the incidence of concomitant Hypokalaemia. Ann. Clin. Biochem. 1992: 29: 64 – 6

Crook MA. et al Department Chemical Pathology, Guys Hospital, London. Severe hypophosphataemia related to Re-feeding. Nutrition: 12 (7-8): 538 – 9 1996 July – August.

Dwyer K. et al. Severe Hypophosphataemia in Postoperative Patients. Nutr. In. Clin. Practice 1992: 7: 279 – 83

Editorial: Treatment of severe Hypophosphataemia. Lancet 1981: 2 (8249): 734

Gonzalez. et al. The incidence of the Re-feeding syndrome in cancer patients who receive artificial nutrition treatment 11(2): 98 – 101, 1996 March – April. Nutrition Hospitalanna, Mexico

Hernandez-Aranda. Et al 1997 October – December 62 (4) 260 – 5 Rev. Gastroenterol mex Malnutrition and TPN: A cohort study to determine the incidence of Re-feeding syndrome.

Hodgson SF. & Hurley DL. Acquired Hypophosphataemia. Endocrin & Metab. Clin N Am. 1993: 22 (2): 397 – 409

Klein CJ. Overfeeding macronutrients to critically ill adults: metabolic complications Journal of American Dietetic Association 1998.

Maier-Dobersberger T. & Lochs H. Enteral Supplementation of Phosphate does not Prevent Hypophosphataemia During Re-feeding of Cachectic Patients. J. Parenteral & Enteral Nutr. 1994: 18 (2): 182 – 4

Mariik PE, Bedigan MK. Re-feeding hypophosphataemia in critically ill patients in an intensive care unit. A prospective study. Department of critical care medicine, Arch Surg 1996 October 131 (10): 1043 – 7

McAtear Carol. March 1999. Current perspectives in enteral nutrition in adults. BAPEN

Melchoir JC. 1998 November 1 (6) 481 – 5 Current Opinion Clinical Nutrition Metabolic Care from Malnutrition to Re-feeding during anorexia nervosa.

Oxford Radcliffe Hospital. November 1996: Re-feeding syndrome: Guidelines, Helen Dewar, Dietitian & Rita Howarth, Chemical Pathologist

Patterson CR. Hypophosphataemia: A Dangerous Disorder. Nutr. 1996: 12: 540 – 1



## WAHT-NUT-006

This guideline has been printed from the Worcestershire Acute Hospitals NHS Trust intranet on  
06/05/2020,14:21

It is the responsibility of every individual to check that this is the latest version/copy of this document.

PENG lecture notes year 2000

Rosenberger K. Management of Electrolyte Abnormalities: Hypocalcaemia, Hypomagnesaemia and Hypokalaemia. J.Am Acad. Nurs. Practitioners. 1998: 10 (5): 209 – 17

Ryan MF. The role of Magnesium in Clinical Biochemistry an overview. Ann. Clin. Biochem. 1991: 28: 19 – 26

Scot M. et al 1990 volume 14 No. 1 Journal Parenteral and Enteral Nutrition. The Re-feeding syndrome: A review.

Solomon SM. & Kirby DF. The Re-feeding Syndrome: A review. J. Parenteral & Enteral Nutrition 1990: 14: 90 – 7

Vanatta JB. et al. Efficacy of Intravenous Phosphorous Therapy in the Severely Hypophosphataemic Patient. Arch. Int. Med. 1981: 141: 885 – 7

National Institute for Health and Clinical Excellence; Nutrition support in adults Clinical Guideline 2006

BAPEN (2012) Re-feeding Syndrome: Identification of those at risk – decision tree,  
<http://www.bapen.org.uk/pdfs/decision-trees/refeeding-syndrome.pdf> (last accesses 20/02/15)

Liverpool (2011) Trust Clinical Policy, Management of re-feeding syndrome

## WAHT-NUT-006

This guideline has been printed from the Worcestershire Acute Hospitals NHS Trust intranet on  
06/05/2020,14:21

It is the responsibility of every individual to check that this is the latest version/copy of this document.

### CONTRIBUTION LIST

#### Key individuals involved in developing the document:

| Name                | Designation                   |
|---------------------|-------------------------------|
| Dr. Thea Haldane    | Consultant Gastroenterologist |
| Jo Brown            | Senior Dietitian, WRH         |
| Sarah Trenbirth     | Senior Dietitian, WRH         |
| Sue Dickinson       | Chief Dietitian, AH           |
| Dorota Amador-Bueno | Senior Dietitian, KH          |
| Keith Hinton        | Pharmacist, WRH               |
| Jo Cheetham         | Nurse Practitioner, WRH       |

#### Circulated to the following individuals for comments:

| Name                 | Designation                         |
|----------------------|-------------------------------------|
| Nalinee Owen         | Dietetic Manager                    |
| All Acute Dietitians | AH, WRH, KH                         |
| Dr Aldulaimi         | Consultant Gastroenterologist, ALEX |
| Dr Ahmad             | Consultant Gastroenterologist, ALEX |
| Dr Prabhakaran       | Gastro Medics, ALEX                 |
| Dr Gee               | Consultant Gastroenterologist, WRH  |
| Dr Hudson            | Consultant Gastroenterologist, WRH  |
| Dr Elagib            | Consultant Gastroenterologist, WRH  |
| Dr Jenkins           | Consultant Endocrinologist, WRH     |
| Mr Lake              | Consultant Surgeon, WRH             |
| Dr Sellors           | Consultant Anaesthetics, WRH        |
| Dr Mitchell          | Consultant Anaesthetics, ALEX       |

#### Circulated to the chair of the following committee's / groups for comments:

| Name            | Committee / group                          |
|-----------------|--|
| Sonya Murray    | Chair of Nutrition and Hydration Committee |
| Alison Smith    | Chair of Medicines Safety Committee        |
| Steve Graystone | Director of Critical Care, Patient Safety  |

## WAHT-NUT-006

This guideline has been printed from the Worcestershire Acute Hospitals NHS Trust intranet on  
06/05/2020,14:21

It is the responsibility of every individual to check that this is the latest version/copy of this document.

### Supporting Document 1 - Equality Impact Assessment Tool

To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.

|    |   | Yes/No | Comments |
|----|---|--------|----------|
| 1. | <b>Does the policy/guidance affect one group less or more favourably than another on the basis of:</b>      |        |          |
|    | Race  | No     |          |
|    | Ethnic origins (including gypsies and travellers)   | No     |          |
|    | Nationality   | No     |          |
|    | Gender  | No     |          |
|    | Culture   | No     |          |
|    | Religion or belief  | No     |          |
|    | Sexual orientation including lesbian, gay and bisexual people   | No     |          |
|    | Age   | No     |          |
| 2. | <b>Is there any evidence that some groups are affected differently?</b>                                     | No     |          |
| 3. | <b>If you have identified potential discrimination, are any exceptions valid, legal and/or justifiable?</b> | N/A    |          |
| 4. | <b>Is the impact of the policy/guidance likely to be negative?</b>  | No     |          |
| 5. | <b>If so can the impact be avoided?</b>   | N/A    |          |
| 6. | <b>What alternatives are there to achieving the policy/guidance without the impact?</b>                     | N/A    |          |
| 7. | <b>Can we reduce the impact by taking different action?</b>   | N/A    |          |

If you have identified a potential discriminatory impact of this key document, please refer it to Human Resources, together with any suggestions as to the action required to avoid/reduce this impact.

For advice in respect of answering the above questions, please contact Human Resources.

## WAHT-NUT-006

This guideline has been printed from the Worcestershire Acute Hospitals NHS Trust intranet on  
06/05/2020,14:21

It is the responsibility of every individual to check that this is the latest version/copy of this document.

### Supporting Document 2 – Financial Impact Assessment

To be completed by the key document author and attached to key document when submitted to the appropriate committee for consideration and approval.

|    | <b>Title of document:</b>  | <b>Yes/No</b> |
|----|--|---------------|
| 1. | Does the implementation of this document require any additional Capital resources  | No            |
| 2. | Does the implementation of this document require additional revenue  | No            |
| 3. | Does the implementation of this document require additional manpower   | No            |
| 4. | Does the implementation of this document release any manpower costs through a change in practice   | No            |
| 5. | Are there additional staff training costs associated with implementing this document which cannot be delivered through current training programmes or allocated training times for staff | No            |
|    | Other comments:  |               |

If the response to any of the above is yes, please complete a business case and which is signed by your Finance Manager and Directorate Manager for consideration by the Accountable Director before progressing to the relevant committee for approval

---

### Appendix 1

## WAHT-NUT-006

This guideline has been printed from the Worcestershire Acute Hospitals NHS Trust intranet on  
06/05/2020,14:21

It is the responsibility of every individual to check that this is the latest version/copy of this document.

### Electrolyte Supplementation in Re-feeding Syndrome

| ELECTROLYTE | SUPPLEMENTATION METHOD   | ADDITIONAL COMMENTS   |
|-------------|--|---|
| PHOSPHATE   | Refer to Trust guideline WAHT-PHA-011<br><a href="http://nww.worcsacute.nhs.uk/EasysiteWeb/getresource.axd?AssetID=11948&amp;type=full&amp;servicetype=Attachment">http://nww.worcsacute.nhs.uk/EasysiteWeb/getresource.axd?AssetID=11948&amp;type=full&amp;servicetype=Attachment</a>   | Check calcium, potassium and phosphate levels after phosphate infusion.<br><br>Use lower doses in renal impairment (consult pharmacy) |
| POTASSIUM   | <u>Level below 2.5mmol/l, if symptomatic or unable to take orally</u><br>20mmol in 500mls or 40mmol in 1000mls of 0.9% sodium chloride at a maximum recommended rate of 10mmol per hour. Repeat as necessary after measuring potassium levels.<br>NB Higher concentrations are used in the ITU/HDU setting for patients with central venous access.<br><br><u>Level above 2.5 mmol/l and able to take orally</u><br>Sando-K tablets 4 to 8 tablets per day in divided doses. |   |
| MAGNESIUM   | Refer to Trust guideline WAHT-PHA-012<br><a href="http://nww.worcsacute.nhs.uk/EasysiteWeb/getresource.axd?AssetID=11950&amp;type=full&amp;servicetype=Attachment">http://nww.worcsacute.nhs.uk/EasysiteWeb/getresource.axd?AssetID=11950&amp;type=full&amp;servicetype=Attachment</a>   |   |